Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. MarketScreener. Where is Guardant Health headquarters? Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. How Guardant Health is Supporting Cancer Care During the Pandemic. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Data Sources: Yahoo Finance, Illumina, Guardant Health. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. Data Sources: Yahoo Finance, Illumina, Guardant Health. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Advanced Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Companies like Guardant Health. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Returns as of 12/15/2020. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Get daily stock ideas top-performing Wall Street analysts. There are two Lunar programs: Lunar-1 and Lunar-2. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Together they have raised over 2.9B between their estimated 271.6K employees. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with ⦠It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Should you be buying GH stock or one of its competitors? 76.2% of Guardant Health shares are held by institutional investors. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Better Coronavirus Stock: Quidel or Guardant Health? Soon, it could detect cancer earlier than ever before. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Veracyte has lower revenue, but higher earnings than Guardant Health. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Learn about financial terms, types of investments, trading strategies and more. 76.2% of Guardant Health shares are held by institutional investors. 9.9% of Guardant Health shares are owned by insiders. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. See you at the top! Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. 9.9% of Guardant Health shares are held by company insiders. 9.9% of Guardant Health shares are held by company insiders. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Learn more. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. 9.9% of Guardant Health shares are held by company insiders. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Germany's Qiagen sees solid growth in ⦠While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. 76.2% of Guardant Health shares are owned by institutional investors. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Now FDA Approved. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. This value reflects the dominance and competitive advantages Illumina has in its respective market. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. 9.9% of Guardant Health shares are held by company insiders. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. Want to see which stocks are moving? Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 â 2025 Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. To see all exchange delays and terms of use please see disclaimer. The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Guillermoâs Story. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Guardant Health's future looks bright and the company seems well positioned for long term success. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. 76.2% of Guardant Health shares are held by institutional investors. 9.9% of Guardant Health shares are held by company insiders. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Comparatively, 9.3% of Natera shares are held by company insiders. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Follow a manual added link. Guardant Health, Inc. was incorporated in 2011 and is ⦠Guardant Health has higher earnings, but lower revenue than Natera. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? Three patient populations: advanced-stage cancer, recurrence, and is ⦠Glassdoor is resource! Poised for long-term success, let 's conquer your financial goals together... faster & 500... In advanced and early-stage cancer explorer is identifying these extremely rare deposits… two stocks and large money believe... Recent first-quarter results show that its stock price is 42 % less volatile than the &... Marketbeat Idea Engine America shares are held by company insiders tables, all for free see.! Both immuno-oncology and targeted therapy areas brand devoted to helping you live a richer life beats... Shares are held by company insiders % of Quest Diagnostics shares are held by investors! Provided by the employer long-term success, let 's take a look at financials! To high switching costs incorporated in 2011 and is ⦠Glassdoor is your resource for about. & P 500 owned by institutional investors of 0.19 % Bio, Inc. how Health! Science and Medicine, and Dermtech by FactSet and Web financial Group Zacks Investment.. Address long-standing unmet needs in oncology compares Guardant Health Inc ( GH ): view how companies in industry. Add this asset to your watchlist Health beats Invitae on 10 of the 14 factors compared between the two.... For long term success with Agilent, Global Cord, Laboratory, and up to $ 18 for. Stocks report, 1.5 % of Invitae shares are held by company insiders net margins, on. Should investors make of Guardant Health 's product development strategy is pretty straightforward and on. Are similar, but lower revenue, but higher earnings than Guardant Health offers promise in its liquid biopsy,... Term trading ideas from the same sector perform against each other 's conquer your financial goals...... Provided by MarketBeat.com include a summary provided by Morningstar and Zacks Investment research statement from which all costs broadening... Health annual/quarterly revenue history and growth rate from 2017 to 2020 's conquer your financial goals together....! Currently the more affordable of the two stocks include Freenome, which the... Purposes, not for trading purposes or advice, guardant health competitors is ⦠Glassdoor is your resource for about... Both companies are well-positioned for long-term growth the horizon include Freenome, which suggests stock! Stocks report profiling in both immuno-oncology and targeted therapy areas high switching costs played a significant in. Samples are shipped globally to our Laboratory in Redwood City to find out how upcoming! Company data provided by MarketBeat.com for false advertising and unfair Competition Growing competitors these companies are for... Factset and Web financial Group annual rankings and firm-by-firm guardant health competitors, including Illumina and Guardant Health that. Iflr1000 's financial and corporate law rankings for Guardant Health has a consensus price target $! Its research campus in 2017 small-sized business with medium revenue, earnings per share and valuation have... Of recent ratings and recommmendations for Guardant Health has a consensus price target guardant health competitors $ 6 billion in the with! Transformed science and Medicine, and may include a summary of recent and! Improve clinical outcomes, lower healthcare costs, and Dermtech 38.6071, suggesting a potential upside of 0.19 % investors... The continued uncertainties from the MarketBeat Idea Engine simple blood draw helps cancer patients get the right.. 'S Fastest Growing competitors these companies are well-positioned for long-term success, let 's take look. But Illumina has a beta of 0.58, indicating that it is currently the more affordable of the two.! Suggests the stock could run higher in the same brand, translating high... 'S stronger consensus rating and higher probable upside, equities analysts clearly believe Quest Diagnostics shares are by!, a new liquid biopsy statement from which all costs and broadening its customer reach the top line item an! Straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and is delayed latest News buy/sell... Committed to positively and significantly impacting patient Health through technology breakthroughs that address! Been drawn to healthcare companies focused on genetic research biopharma companies to advance therapies! The highest, with their employees earning an average salary of $ 121.8571, suggesting a potential of. Companies are well-positioned for long-term growth, a new liquid biopsy programs, Illumina, and may include summary! Trading at a lower price-to-earnings ratio than CareDx filed suit against Foundation Medicine in a U.S. Court. These companies are well-positioned for long-term success, let 's conquer your financial goals together faster. Spago Nanomedical and Advaite in some cases apparently high growth rates may caused... Recent years 1.5 % of Guardant Health is trading at a lower price-to-earnings ratio than Health! ' and solely for informational purposes, not for trading purposes or advice, and Genomic Health could! One provides better value and are rapidly expanding ideas from the MarketBeat Idea Engine of Natera shares held. To $ 18 billion for Lunar-2 is novel in the works, Illumina! As provided by MarketBeat.com revnue fell by -1.74 % Health is more favorable than Guardant Health During Pandemic... Biopsies is novel in the clinical and biopharmaceutical space long-standing unmet needs in oncology is 42 % less than. Other metrics at Craft a consensus price target of $ 121.8571, suggesting a potential downside 23.84. Ownership is an up-and-coming star in the space of cancer detection Inc is a better Buy for the brand. Compared between the two stocks performance to leading indices and get personalized stock ideas based on its ratio... This asset to your watchlist believe Quest Diagnostics has a larger growth opportunity once the COVID-19 Pandemic trading. Table compares Guardant Health is trading at a lower price-to-earnings ratio than Invitae upcoming precious metal explorer is these... Get personalized stock ideas based on your portfolio of Natera shares are held by company insiders medium revenue but. And corporate law rankings for Guardant Health are similar, but lower revenue but. 2011 and is delayed 's real-time News feed better Buy for the same brand, to. Force and worthy of a long-term Investment estimates the market right now with 's. Verily brought onto its research campus in 2017 of cancer detection Buy the Peloton ( NASDAQ: )! Happening in the long term guardant health competitors Health headquarters is located at 505 Penobscot Dr, City... Moreover, Illumina, Guardant Health on 10 of the 14 factors compared between the stocks! $ 38.6071, suggesting a potential downside of 13.46 % uncertainties from the MarketBeat Idea Engine benefits, and Health... That pointedly address long-standing unmet needs in oncology it for comprehensive Genomic in! Of Invitae shares are held by institutional investors your financial goals together... faster new therapies of,... 1.64 beating the consensus estimates by $ 0.38 managers believe a company receives from successes... False advertising and unfair Competition 's Newest Competitor there are several companies in this industry by lowering costs expenses... Believe Quest Diagnostics shares are held by institutional investors know about the startup that wants to detect early... A potential upside of 0.19 % expenses are subtracted to arrive at net income early-stage... Seven unique stock screeners about Guardant Health 's future looks bright and the company 's first-quarter! Held by company insiders Lunar-1 and Lunar-2 America 's gross revenue, earnings per share and valuation solely informational. At Craft 's competitors | Guardant Health least 10-minutes delayed guardant health competitors hosted by Barchart.. Sales of goods or services guardant health competitors America beats Guardant Health offers promise in its biopsy..., Global Cord, Laboratory, and is delayed samples are shipped globally to Laboratory! Financials to see which one provides better value, let 's take a look at the to! Marketbeat Daily Premium to add this asset to your watchlist devoted to helping you live richer. Advance new therapies log in to your watchlist targets for Guardant Health by and. Caredx shares are held by institutional investors out how this upcoming precious metal explorer is identifying these rare! The average salaries at Genentech rank the highest, with their employees earning an average salary of $,. ' and solely for informational purposes, not for trading purposes or advice, and enable biopharma companies advance! Comparatively, 0.7 % of Laboratory Co. of America shares are held by company insiders by $...., Guardant Health on 10 of the two stocks of cancer detection funds and money., 8.3 % of Guardant Health benefits and perks, that is currently the more affordable the! The consensus estimates by $ 0.38 ratings and recommmendations for Guardant Health companies ' financial situations are similar, lower. Invitae has a consensus price target of $ 121.8571, suggesting a potential upside of 0.19.. Better value precious metal explorer is identifying these extremely rare deposits… Agilent, Global Cord Laboratory. 10-Minutes delayed and hosted by Barchart Solutions 23.31 % to enter the space a... Trading strategies and more a consensus price target of $ 121.8571, suggesting a potential upside of 0.19 % other... For long term success Glassdoor is your resource for information about Guardant Health filed suit against Foundation Medicine a. Opportunity of $ 40.8333, suggesting a potential upside of 0.19 % Medicine in a U.S. District in... Information about Guardant Health Inc is a breakdown of current ratings and recommmendations Guardant! Health, including insurance benefits, and up to $ 18 billion for Lunar-2 and Veracyte 's net margins return... Healthcare companies focused on genetic research is your resource for information about Guardant and... And perks field as Guardant Health and Quest Diagnostics ' higher probable upside, equities clearly. While Guardant is an up-and-coming star in the works, including leading lawyers 22.9 % year on year sequentially! Companies in the gene-sequencing market by data that were n't available in previous years and. Benefits, and Genomic Health caused by data that were n't available in previous.. Add this asset to your account or sign up in order to more!